Heineken warns pubs over impact of weight-loss drugs
The brewer advises British hospitality businesses to offer smaller portions and more alcohol-free drinks.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
Heineken is warning British pubs and bars that weight-loss medicines could reduce demand for beer. The brewer bases the warning on a presentation for hospitality customers seen by Reuters.
The presentation names drugs from the so-called GLP-1 group, such as Ozempic and Wegovy, as a potential threat to beer sales. According to the brewer, users may feel full more quickly, have less appetite for alcohol and consequently order smaller quantities.
Heineken is therefore advising hospitality businesses to offer, among other things, half-pints, alcohol-free and low-alcohol drinks, and smaller dishes. The presentation warns that traditional drinking occasions involving several glasses may become harder to sustain if use of these medicines continues to increase.
The brewer is not saying that the medicines are already demonstrably causing a fall in British beer sales. Heineken told Reuters that the company is seeing changes in consumption patterns and plans to monitor them further in 2027. The presentation is therefore primarily a warning and preparation for a possible market effect.
Research by market researcher Circana does, according to Reuters, point to lower alcohol spending among households in which someone uses GLP-1 medicines. After two years, monthly alcohol spending in that group was about 7 per cent lower than in comparable households without a user; beer spending was about 13 per cent lower. These figures are not a direct measurement of Heineken sales.
The development is relevant to Dutch brewers and hospitality businesses because Heineken is a Dutch group and Europe is its largest sales region. At the same time, it is unclear how large the effect will be in the Netherlands. Possible differences in use, prescriptions, income groups and drinking habits may be relevant.
The warning also raises the question of how brewers should respond to possible changes in demand for alcohol. Other brewers, including Carlsberg, have also said, according to Reuters, that there is still insufficient evidence to identify GLP-1 medicines as a clear cause of changing beer consumption.
Also show where in Europe and in the world
One story, several perspectives
What is established
- Heineken warned British hospitality customers about potentially changing drinking behaviour among users of GLP-1 medicines.
- The brewer advised smaller portions and more alcohol-free or low-alcohol options.
- The available figures show an association with lower alcohol spending, but do not prove that GLP-1 medicines are the cause of developments in the beer market as a whole.
Left
Arguments The development shows that public health and commercial interests do not automatically coincide. Falling alcohol consumption can bring health benefits; policy should continue to support prevention and affordable care for problematic alcohol use.
Values Public health, consumer protection and reducing the harm caused by addiction.
Consequences Lower alcohol sales may bring health benefits, but hospitality businesses and employees may lose revenue and jobs.
Centre
Arguments The market must adapt to changing consumer behaviour without drawing conclusions before independent sales data are available. Transparent information and room for alcohol-free alternatives are logical steps.
Values Evidence, proportionality and room for consumer choice.
Consequences Brewers and hospitality businesses can gradually adapt their offerings, while regulators continue to monitor claims about medicines and alcohol.
Right
Arguments Business owners should be free to decide how they adapt their ranges; a company warning is no reason for new government intervention in legal products.
Values Free enterprise, personal responsibility and limited regulation.
Consequences Competition may stimulate innovation in low-alcohol products, but companies also bear the risk of changing demand themselves.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The article’s core is supported by Reuters and an independent second source. Figures and uncertainties are explicitly attributed and not presented as a proven causal relationship.
- confirmed Heineken warned British hospitality customers about possible lower beer sales due to GLP-1 medicines. — Mentioned in the Reuters report on the presentation. source
- confirmed Heineken advised, among other things, half-pints and alcohol-free drinks. — Reuters describes these recommendations; RetailDetail confirms them. source
- confirmed Alcohol spending in the Circana group mentioned was about 7 per cent lower and beer spending about 13 per cent lower. — The figures are reproduced with source attribution and period context from Reuters. source
Editor's note
It is certain that Heineken warned British hospitality customers about the possible effect. What remains uncertain is the actual impact on beer sales; the available figures are not a direct measurement of Heineken sales.Sources
- Heineken document reveals worries over weight-loss drugs and beer sales — Reuters via Investing.com
- Heineken warns: weight-loss products threaten beer sales — RetailDetail
More on this in Dutch media
- NU.nl — „heineken afslankmedicatie”
- De Telegraaf — „heineken afslankmedicatie”
- Trouw — „heineken afslankmedicatie”